Shanghai InnoStar Bio-tech (688710.SH): Ao Peng Partnership plans to reduce its shareholding by no more than 1%
Yinuo Si (688710.SH) announced that Aopeng Group plans to reduce its holdings of the company's shares through centralized bidding trading within 3 months after the disclosure of the announcement. The number of shares to be reduced shall not exceed 1,409,800 shares, accounting for no more than 1% of the total share capital of the company. In any consecutive 90 natural days, the total number of shares to be reduced shall not exceed 1% of the total number of company shares.
Shanghai InnoStar Bio-tech (688710.SH) announced that Aopeng Partnership plans to reduce its holdings of the company's shares through concentrated auction trading within 3 months of the announcement date, starting from 15 trading days after the announcement. The number of shares to be sold shall not exceed 1,409,800 shares, accounting for no more than 1% of the company's total share capital. The total number of shares sold within any consecutive 90 natural days shall not exceed 1% of the company's total share capital.
Aopeng Partnership is an employee shareholding platform of the company, through which some directors, senior management personnel, and core technical personnel indirectly hold company shares.
Related Articles
CHINA LESSO (02128) and Guangdong Liansu Electric have signed a parts supply agreement.
Jiangsu Hengrui Pharmaceuticals (01276): SHR-2906 Injection Obtains Drug Clinical Trial Approval Letter.
Jiangsu Hengrui Pharmaceuticals (01276): SHR-9539 injection, HRS-3738 tablets received the approval notice for drug clinical trials.
CHINA LESSO (02128) and Guangdong Liansu Electric have signed a parts supply agreement.
Jiangsu Hengrui Pharmaceuticals (01276): SHR-2906 Injection Obtains Drug Clinical Trial Approval Letter.
Jiangsu Hengrui Pharmaceuticals (01276): SHR-9539 injection, HRS-3738 tablets received the approval notice for drug clinical trials.
